Clinical trials: Dry Eye Disease
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome
A Multi-Center, Phase 2/3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Voclosporin Ophthalmic Solution (0.05%, 0.10%, 0.20%) Compared to Vehicle in Subjects…
- Trial name
- AUDREY (NCT04147650)
- Testing
- 0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS
- Where
- 9 sites in United States
- Volunteers
- 508 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Keratoconjunctivitis Sicca
Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
This is a randomized, double-masked, vehicle-controlled study of the safety and efficacy of OTX-101 (0.09% cyclosporine nanomicellar solution) in the treatment of keratoconjunctivitis sicca to be conducted at approximately 50…
- Trial name
- Emerald (NCT02688556)
- Testing
- cyclosporine, vehicle of OTX-101
- Where
- 3 sites in United States
- Volunteers
- 745 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Dry Eye Syndrome
SYSTANE® Family - Meibomian Deficiency
The purpose of this study was to assess the efficacy of the SYSTANE® family of products (SYSTANE® Lid Wipes, SYSTANE® BALANCE Lubricant Eye Drops, and SYSTANE® Vitamins) on meibomian gland functionality in subjects with lipid…
- Trial name
- M-12-077 (NCT01733745)
- Testing
- SYSTANE® Lid Wipes, SYSTANE® BALANCE, SYSTANE® Vitamins
- Volunteers
- 26 people
- Sponsor
- Alcon Research
Dry Eye
The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
The TRANQUILITY 2 Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects…
- Trial name
- NCT05062330
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Dry Eye Disease
A Study Designed to Evaluate Tear Production
The purpose of this study is to evaluate tear production following acute administration of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) in subjects with dry eye disease (DED).
- Trial name
- NCT06544707
- Testing
- 0.003% AR-15512 ophthalmic solution
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Alcon Research
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 1 (NCT02813265)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 60 sites in United States
- Volunteers
- 918 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Sjogren's Syndrome
A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome
The present study will examine the role of circulating RNA complexed with autoantibodies and immune complexes and its role in activation of inflammatory pathways in patients with primary Sjogren's syndrome.
- Trial name
- RSLV-132 (NCT03247686)
- Testing
- RSLV-132
- Where
- 2 sites in United Kingdom
- Volunteers
- 28 people
- Sponsor
- Resolve Therapeutics
Dry Eye Disease
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
Efficacy study of ecabet ophthalmic solution in dry eye disease
- Trial name
- NCT00667004
- Testing
- ecabet ophthalmic solution
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- Bausch & Lomb Incorporated
Chronic Graft-versus-host Disease
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures.
- Trial name
- DROPS-2 (NCT02040623)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Rigel Pharmaceuticals
Long Term Follow up Dry Eye Disease
Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
The objective of this safety long-term follow-up study was to evaluate the safety of OC-01 Nasal Spray at 6 months and 12 months post treatment in the OPP-002 study (NCT03636061).
- Trial name
- NCT03920215
- Testing
- OC-01 Low Dose, 0.12 mg/mL, OC-01 Mid Dose, 0.6 mg/mL, OC-01 High Dose, 1.2 mg/mL
- Where
- 3 sites in United States
- Volunteers
- 101 people
- Sponsor
- Oyster Point Pharma, Inc.
Dry Eye Syndromes
Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye
This study will evaluate the safety, tolerability and pharmacokinetics of two formulations of cyclosporine ophthalmic emulsion in healthy adults (parallel-group phase).
- Trial name
- NCT01319773
- Testing
- cyclosporine ophthalmic emulsion Formulation A, cyclosporine ophthalmic emulsion Formulation B, cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Allergan
Dry Eye
Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery
This study is designed to assess the tolerability and comfort of peri-operative 0.3% hypromellose eye drops in LASIK surgery patients and to assess whether pre-operative 0.3% hypromellose eye drops add to post-operative comfort…
- Trial name
- NCT00909324
- Testing
- Pre-LASIK 0.3% hypromellose, Post-LASIK 0.3% hypromellose
- Where
- India
- Volunteers
- 170 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-Related Macular Degeneration
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid…
- Trial name
- SWIFT (NCT04264819)
- Testing
- RTH258/Brolucizumab
- Where
- 51 sites in France
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye
Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease
This is a phase 3 study to evaluate the safety and efficacy of OmegaD softgels for the treatment of dry eye disease. A daily dose of 2 OmegaD softgels dosed orally BID will be compared to 2 placebo softgels (mineral oil ) dosed…
- Trial name
- NCT04181593
- Testing
- Omega 3 fatty acid
- Where
- 14 sites in United States
- Volunteers
- 322 people
- Sponsor
- OmegaD LLC
Dry Eye
The Effect of SYSTANE® BALANCE on Tear Film Break Up Time in Dry Eye Subjects
The purpose of this study was to evaluate the ability of SYSTANE® BALANCE dosed 4 times a day for 30 days to increase non-invasive tear film break up time over baseline, compared to a saline control, in dry eye subjects with…
- Trial name
- NCT01718028
- Testing
- Propylene glycol 0.6% ocular emulsion, Sodium chloride 0.9% saline solution
- Where
- Argentina
- Volunteers
- 51 people
- Sponsor
- Alcon Research
Dry Eye
Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal Sensation and Dry Eye
This is a multicenter evaluation of the effects of the cataract extraction and limbal relaxing incisions (LRI) on corneal sensation and dry eye signs and symptoms.
- Trial name
- NCT01161771
- Testing
- Cataract Surgery and Limbal relaxing incision
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Allergan
Dry Eye
A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease
Protocol AXR201701 is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study carried out in 2 stages (Stage 1: AXR-159 Ophthalmic Solution (30 mg/mL or 50 mg/mL); Stage 2: AXR-159 Ophthalmic Solution…
- Trial name
- NCT03598699
- Testing
- AXR-159, Vehicle
- Where
- 3 sites in United States
- Volunteers
- 102 people
- Sponsor
- AxeroVision, Inc.
Dry Eye Disease (DED)
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).
- Trial name
- NCT03333057
- Testing
- NOV03
- Where
- 11 sites in United States
- Volunteers
- 336 people
- Sponsor
- Novaliq GmbH
Age-related Macular Degeneration
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
The purpose of this study was to evaluate the efficacy and safety of two different brolucizumab 6 mg dosing regimens in patients with visual impairment due to age-related macular degeneration (AMD) who have previously received…
- Trial name
- FALCON (NCT04679935)
- Testing
- Brolucizumab
- Where
- 19 sites in Germany, Switzerland
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye
A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)
The purpose of this study is to evaluate the efficacy of three different concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution compared to placebo in the treatment of dry eye.
- Trial name
- NCT00926185
- Testing
- Lifitegrast
- Where
- 5 sites in United States
- Volunteers
- 230 people
- Sponsor
- Shire